Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.

Thomas-Matthias Scherzer; Albert Friedrich Stättermayer; Michael Strasser; Hermann Laferl; Andreas Maieron; Rudolf Stauber; Christian Datz; Emina Dulic-Lakovic; Petra Steindl-Munda; Harald Hofer; Peter Ferenci

doi:10.1002/hep.24546

Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.

Thomas-Matthias Scherzer, Albert Friedrich Stättermayer, Michael Strasser (Co-author), Hermann Laferl, Andreas Maieron, Rudolf Stauber, Christian Datz, Emina Dulic-Lakovic, Petra Steindl-Munda, Harald Hofer, Peter Ferenci

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

28 Citations (Web of Science)

Original language	English
Pages (from-to)	1518-1526
Journal	HEPATOLOGY
Volume	54
Issue number	5
DOIs	https://doi.org/10.1002/hep.24546
Publication status	Published - 2011

Keywords

RAPID VIROLOGICAL RESPONSE
TREATMENT-NAIVE PATIENTS
GENOTYPE 1 INFECTION
PLUS RIBAVIRIN
TREATMENT DURATION
SPONTANEOUS CLEARANCE
(40 KD)/RIBAVIRIN
GENETIC-VARIATION
RANDOMIZED-TRIAL
POLYMORPHISM

Access to Document

10.1002/hep.24546

Cite this

Scherzer, T.-M., Stättermayer, A. F., Strasser, M., Laferl, H., Maieron, A., Stauber, R., Datz, C., Dulic-Lakovic, E., Steindl-Munda, P., Hofer, H., & Ferenci, P. (2011). Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. HEPATOLOGY , 54(5), 1518-1526. https://doi.org/10.1002/hep.24546

Scherzer, Thomas-Matthias ; Stättermayer, Albert Friedrich ; Strasser, Michael et al. / Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. In: HEPATOLOGY 2011 ; Vol. 54, No. 5. pp. 1518-1526.

@article{f479bca5a6434028be92d577a348a35c,

title = "Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.",

keywords = "RAPID VIROLOGICAL RESPONSE, TREATMENT-NAIVE PATIENTS, GENOTYPE 1 INFECTION, PLUS RIBAVIRIN, TREATMENT DURATION, SPONTANEOUS CLEARANCE, (40 KD)/RIBAVIRIN, GENETIC-VARIATION, RANDOMIZED-TRIAL, POLYMORPHISM",

author = "Thomas-Matthias Scherzer and St{\"a}ttermayer, {Albert Friedrich} and Michael Strasser and Hermann Laferl and Andreas Maieron and Rudolf Stauber and Christian Datz and Emina Dulic-Lakovic and Petra Steindl-Munda and Harald Hofer and Peter Ferenci",

year = "2011",

doi = "10.1002/hep.24546",

language = "English",

volume = "54",

pages = "1518--1526",

journal = "HEPATOLOGY ",

issn = "0270-9139",

number = "5",

}

Scherzer, T-M, Stättermayer, AF, Strasser, M, Laferl, H, Maieron, A, Stauber, R, Datz, C, Dulic-Lakovic, E, Steindl-Munda, P, Hofer, H & Ferenci, P 2011, 'Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.', HEPATOLOGY , vol. 54, no. 5, pp. 1518-1526. https://doi.org/10.1002/hep.24546

Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. / Scherzer, Thomas-Matthias; Stättermayer, Albert Friedrich; Strasser, Michael (Co-author) et al.
In: HEPATOLOGY , Vol. 54, No. 5, 2011, p. 1518-1526.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.

AU - Scherzer, Thomas-Matthias

AU - Stättermayer, Albert Friedrich

AU - Strasser, Michael

AU - Laferl, Hermann

AU - Maieron, Andreas

AU - Stauber, Rudolf

AU - Datz, Christian

AU - Dulic-Lakovic, Emina

AU - Steindl-Munda, Petra

AU - Hofer, Harald

AU - Ferenci, Peter

PY - 2011

Y1 - 2011

KW - RAPID VIROLOGICAL RESPONSE

KW - TREATMENT-NAIVE PATIENTS

KW - GENOTYPE 1 INFECTION

KW - PLUS RIBAVIRIN

KW - TREATMENT DURATION

KW - SPONTANEOUS CLEARANCE

KW - (40 KD)/RIBAVIRIN

KW - GENETIC-VARIATION

KW - RANDOMIZED-TRIAL

KW - POLYMORPHISM

U2 - 10.1002/hep.24546

DO - 10.1002/hep.24546

M3 - Original Article

C2 - 22006276

SN - 0270-9139

VL - 54

SP - 1518

EP - 1526

JO - HEPATOLOGY

JF - HEPATOLOGY

IS - 5

ER -

Scherzer TM, Stättermayer AF, Strasser M, Laferl H, Maieron A, Stauber R et al. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. HEPATOLOGY . 2011;54(5):1518-1526. doi: 10.1002/hep.24546